Extracellular vesicles and COPD: foe or friend?
Abstract Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory airway disease characterized by progressive airflow limitation. The complex biological processes of COPD include protein hydrolysis tissue remodeling, innate immune inflammation, disturbed host-pathogen response, abnorma...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-05-01
|
Series: | Journal of Nanobiotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12951-023-01911-5 |
_version_ | 1797831888382984192 |
---|---|
author | Jiankang Wu Yiming Ma Yan Chen |
author_facet | Jiankang Wu Yiming Ma Yan Chen |
author_sort | Jiankang Wu |
collection | DOAJ |
description | Abstract Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory airway disease characterized by progressive airflow limitation. The complex biological processes of COPD include protein hydrolysis tissue remodeling, innate immune inflammation, disturbed host-pathogen response, abnormal cellular phenotype conversion, and cellular senescence. Extracellular vesicles (EVs) (including apoptotic vesicles, microvesicles and exosomes), are released by almost all cell types and can be found in a variety of body fluids including blood, sputum and urine. EVs are key mediators in cell-cell communication and can be used by using their bioactive substances (DNA, RNA, miRNA, proteins and other metabolites) to enable cells in adjacent and distant tissues to perform a wide variety of functions, which in turn affect the physiological and pathological functions of the body. Thus, EVs is expected to play an important role in the pathogenesis of COPD, which in turn affects its acute exacerbations and may serve as a diagnostic marker for it. Furthermore, recent therapeutic approaches and advances have introduced EVs into the treatment of COPD, such as the modification of EVs into novel drug delivery vehicles. Here, we discuss the role of EVs from cells of different origins in the pathogenesis of COPD and explore their possible use as biomarkers in diagnosis, and finally describe their role in therapy and future prospects for their application. Graphical Abstract |
first_indexed | 2024-04-09T14:00:01Z |
format | Article |
id | doaj.art-6f1b7366b5bb43c6a761368ee055b1b5 |
institution | Directory Open Access Journal |
issn | 1477-3155 |
language | English |
last_indexed | 2024-04-09T14:00:01Z |
publishDate | 2023-05-01 |
publisher | BMC |
record_format | Article |
series | Journal of Nanobiotechnology |
spelling | doaj.art-6f1b7366b5bb43c6a761368ee055b1b52023-05-07T11:22:45ZengBMCJournal of Nanobiotechnology1477-31552023-05-0121111310.1186/s12951-023-01911-5Extracellular vesicles and COPD: foe or friend?Jiankang Wu0Yiming Ma1Yan Chen2Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South UniversityDepartment of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South UniversityDepartment of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South UniversityAbstract Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory airway disease characterized by progressive airflow limitation. The complex biological processes of COPD include protein hydrolysis tissue remodeling, innate immune inflammation, disturbed host-pathogen response, abnormal cellular phenotype conversion, and cellular senescence. Extracellular vesicles (EVs) (including apoptotic vesicles, microvesicles and exosomes), are released by almost all cell types and can be found in a variety of body fluids including blood, sputum and urine. EVs are key mediators in cell-cell communication and can be used by using their bioactive substances (DNA, RNA, miRNA, proteins and other metabolites) to enable cells in adjacent and distant tissues to perform a wide variety of functions, which in turn affect the physiological and pathological functions of the body. Thus, EVs is expected to play an important role in the pathogenesis of COPD, which in turn affects its acute exacerbations and may serve as a diagnostic marker for it. Furthermore, recent therapeutic approaches and advances have introduced EVs into the treatment of COPD, such as the modification of EVs into novel drug delivery vehicles. Here, we discuss the role of EVs from cells of different origins in the pathogenesis of COPD and explore their possible use as biomarkers in diagnosis, and finally describe their role in therapy and future prospects for their application. Graphical Abstracthttps://doi.org/10.1186/s12951-023-01911-5Extracellular vesiclesChronic obstructive pulmonary diseasePathogenesisExacerbationDiagnosisTreatment |
spellingShingle | Jiankang Wu Yiming Ma Yan Chen Extracellular vesicles and COPD: foe or friend? Journal of Nanobiotechnology Extracellular vesicles Chronic obstructive pulmonary disease Pathogenesis Exacerbation Diagnosis Treatment |
title | Extracellular vesicles and COPD: foe or friend? |
title_full | Extracellular vesicles and COPD: foe or friend? |
title_fullStr | Extracellular vesicles and COPD: foe or friend? |
title_full_unstemmed | Extracellular vesicles and COPD: foe or friend? |
title_short | Extracellular vesicles and COPD: foe or friend? |
title_sort | extracellular vesicles and copd foe or friend |
topic | Extracellular vesicles Chronic obstructive pulmonary disease Pathogenesis Exacerbation Diagnosis Treatment |
url | https://doi.org/10.1186/s12951-023-01911-5 |
work_keys_str_mv | AT jiankangwu extracellularvesiclesandcopdfoeorfriend AT yimingma extracellularvesiclesandcopdfoeorfriend AT yanchen extracellularvesiclesandcopdfoeorfriend |